What are the indications for caffeine citrate in preterm infants according to gestational age?

Caffeine Citrate Indications in Preterm Infants by Gestational Age

Caffeine citrate is FDA-approved for short-term treatment of apnea of prematurity in infants between 28 and <33 weeks gestational age, though clinical practice commonly extends its use to broader gestational age ranges and indications. 1

FDA-Approved Indication

• Gestational age: 28 to <33 weeks for treatment of apnea of prematurity 1
• Standard dosing: 20 mg/kg loading dose, followed by 5 mg/kg/day maintenance 1

Evidence-Based Expanded Indications by Gestational Age

Very Early Preterm (<28 weeks)

• Caffeine is widely used off-label in extremely preterm infants ≤28 weeks, with 95% receiving treatment in contemporary practice 2
• Median daily doses of 8 mg/kg/day are commonly administered, though this exceeds FDA labeling 2
• Early initiation within 72 hours of life likely reduces chronic lung disease (RR 0.64,95% CI 0.40 to 1.03) and apnea episodes (RR 0.58,95% CI 0.37 to 0.90) in high-risk preterm infants 3
• Prophylactic treatment initiated while on mechanical ventilation may reduce chronic lung disease (RR 0.77,95% CI 0.50 to 1.18) and significantly decreases duration of mechanical ventilation (MD -1.90 days) 3

Standard Preterm Range (28 to <33 weeks)

• This represents the core FDA-approved population for apnea treatment 1
• Clinical trials demonstrate 26.7% of infants achieve zero apnea events by day 2 of treatment versus 8.1% with placebo 1
• Mean reduction of apnea events from 7.2 to 4.9 episodes per 24 hours 1

Late Preterm (34 to <37 weeks)

• Caffeine reduces intermittent hypoxemia in late preterm infants (34+0 to 36+6 weeks) when initiated within 72 hours of birth 4
• The 20 mg/kg/day maintenance dose is most effective, reducing intermittent hypoxemia events from 4.6 to 1.7 events/hour (GM ratio 0.33,95% CI 0.17 to 0.68) 4
• This dose increases mean oxygen saturation to 97.2% versus 96.0% with placebo and reduces time with SpO2 <90% 4
• This represents an important off-label use given the high prevalence of intermittent hypoxemia in this population 4

Timing of Initiation

Prophylactic Early Administration

• Initiation within 72 hours of life for asymptomatic high-risk infants likely reduces chronic lung disease (RR 0.49,95% CI 0.26 to 0.94) compared to treating only symptomatic infants 3
• French neonatal units commonly use systematic prophylaxis with a threshold of 32 weeks gestational age 5
• Evidence supports early administration in infants on mechanical ventilation rather than waiting until extubation 3

Treatment of Symptomatic Apnea

• Traditional approach treats infants after apnea develops, but this may miss the window for optimal chronic lung disease prevention 3
• Waiting for symptoms results in higher rates of chronic lung disease compared to prophylactic treatment 3

Duration of Treatment

• Continue until 33-35 weeks postmenstrual age (37% of units) or 35-37 weeks (53% of units) based on French practice patterns 5
• Require mean of 5 days without apnea before discontinuation 5
• Two-thirds of neonatologists report recurrent apnea beyond 37 weeks requiring continued treatment 5
• Some centers discharge infants home on caffeine, discontinuing by 42-46 weeks postmenstrual age 5

Dosing Considerations

Standard Dosing

• Loading: 20 mg/kg caffeine citrate (10 mg/kg caffeine base) 1
• Maintenance: 5 mg/kg/day caffeine citrate (2.5 mg/kg/day caffeine base) 1

Higher Dosing for Specific Indications

• Periextubation management in <30 weeks gestation: 20 mg/kg/day maintenance reduces extubation failure from 29.8% to 15.0% (NNT = 7) 6
• Late preterm intermittent hypoxemia: 20 mg/kg/day maintenance most effective 4
• Higher doses (loading 30-80 mg/kg, maintenance 12-30 mg/kg) probably reduce bronchopulmonary dysplasia (RR 0.75,95% CI 0.60 to 0.94) but require caution regarding potential toxicity 7

Important Caveats

• Avoid intact cord milking in infants <28 weeks who may receive early caffeine, as this population has specific cord management considerations 8
• Monitor for side effects including tachycardia, feeding intolerance, and jitteriness, though increased doses show similar adverse event rates to standard dosing 7
• Caffeine metabolism is extremely slow in neonates (half-life 3-4 days) with 86% excreted unchanged, requiring dose adjustments in hepatic or renal insufficiency 1
• Real-world practice commonly exceeds FDA labeling in terms of gestational age range, dosing, and duration, with safety data supporting this broader use 2